Objective: The objective of this descriptive study was to compare bone mineral density (BMD) between users of two kinds of once-a-month combined injectable contraceptives (CICs) and control subjects.
Subjects And Methods: This cross-sectional descriptive study included 97 women aged between 20 and 45 years using CICs containing either 25 mg of medroxyprogesterone acetate and 5 mg of estradiol cypionate for 12-82 months or 50 mg of norethindrone enanthate and 5 mg of estradiol valerate for 12-60 months, matched by age (+/-1 year) and body mass index (BMI; kg/m(2)) (+/-1) with users of the TCu 380A intrauterine device as control subjects. BMD was evaluated at the midshaft of the ulna and at the distal section of the radius of the nondominant forearm using double X-ray absorptiometry.
Results: There was no difference in BMD between users of either CIC and nonusers at either section of the forearm studied. There was also no difference in BMD between users of the two CICs at either section of the forearm.
Conclusions: Women aged between 20 and 45 years, currently using one of these two kinds of CICs, presented BMDs similar to those of control subjects paired by age and BMI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.contraception.2006.03.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cannabis use and cognitive biases in people with first-episode psychosis and their siblings.
Psychol Med
November 2024
Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain.
Background: Cannabis use and familial vulnerability to psychosis have been associated with social cognition deficits. This study examined the potential relationship between cannabis use and cognitive biases underlying social cognition and functioning in patients with first episode psychosis (FEP), their siblings, and controls.
Methods: We analyzed a sample of 543 participants with FEP, 203 siblings, and 1168 controls from the EU-GEI study using a correlational design.
Comparison of the Effect of Selective Serotonin and Norepinephrine Reuptake Inhibitors on Bone Mineral Density with Selective Serotonin Reuptake Inhibitors and Healthy Controls.
J Clin Densitom
October 2024
Madalyon Psychiatry Clinic, Levent, İstanbul, Turkey.
Article Synopsis
- * Sixty-three patients on SNRIs (venlafaxine, duloxetine) and sixty patients on SSRIs underwent assessments, showing that SSRI users had lower bone density values compared to SNRI users, who demonstrated normal bone density.
- * The findings suggest that SNRIs, particularly duloxetine, may pose a lower risk for osteoporosis compared to SSRIs, indicating the need for more research to confirm these results.
Examining depression, antidepressants use, and class and their potential associations with osteoporosis and fractures in adult women: Results from ten NHANES cohorts.
J Affect Disord
January 2025
College of Medicine, Health, Qatar University, P.O. Box 2713, Doha, Qatar. Electronic address:
Introduction: Osteoporosis, a significant public health concern, affects millions of adult women globally, leading to increased morbidity and fracture risk. Antidepressant use, prevalent in this demographic, is suggested to influence bone mineral density (BMD), yet evidence remains limited across antidepressant classes.
Objective/aim: We investigated the association between antidepressant use and osteoporosis in a representative sample of adult women in the United States, focusing on different classes of antidepressants and their potential associations with BMD and fracture risk.
Romosozumab versus denosumab in long-term users of glucocorticoids: A pilot randomized controlled trial.
J Intern Med
December 2024
Department of Nuclear Medicine, Tuen Mun Hospital, Hong Kong SAR, China.
Article Synopsis
- - The study aimed to compare the effectiveness of romosozumab (ROMO) and denosumab (DEN) in increasing spine bone mineral density (BMD) in patients using long-term glucocorticoids, specifically those on prednisolone. - Results showed that after 12 months, ROMO significantly increased spine BMD by 7.3% compared to 2.3% with DEN, and this trend continued for both groups at 24 months, although ROMO still had greater gains. - While both treatments were effective, ROMO led to better results for spine BMD, but patients on ROMO reported more injection site reactions.
Prunes May Blunt Adverse Effects of Oral Contraceptives on Bone Health in Young Adult Women: A Randomized Clinical Trial.
Curr Dev Nutr
September 2024
School of Exercise and Nutritional Sciences, San Diego State University, San Diego, CA, United States.
Background: Oral contraceptives (OCs) may promote bone loss, thereby leading to suboptimal bone health later in life. Research is needed to determine whether dietary interventions can blunt OC-related bone loss; prune consumption, shown to be effective in improving bone density in previous studies, could provide a safe and inexpensive solution.
Objectives: The purpose of this study was to determine whether 12 mo of consuming 50 g of prunes daily would prevent bone loss or increase bone accrual in young (18-25 y) OC users.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!